Abstract P3-02-03: Prognostic Value of Circulating Tumor Cells (CTC) in HER-2 Positive Metastatic Breast Cancer (MBC) Patients (pts) Treated with Anti-HER2-Based Therapy

Mario Giuliano(Regione Campania), Massimo Cristofanilli(Cornell University), Vicente Valero(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), BC Handy(Fox Chase Cancer Center), GN Hortobagyi(Fox Chase Cancer Center), Antonio Giordano(University of Siena), JM Reuben(Fox Chase Cancer Center), RH Alvarez(Fox Chase Cancer Center)
Cancer Research
December 1, 2010
10.1158/0008-5472.sabcs10-p3-02-03
Cited by 1

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Curcumin and Cancer
|Nutrients|2019|977